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Objective: Corticosteroids attenuate inflammatory reaction in pediatric heart surgery. Inflammation 
is a source of free oxygen radicals. Children with a cyanotic heart defect are prone to increased 
radical stress during heart surgery. We hypothesized that high-dose methylprednisolone reduces 
inflammatory reaction and thereby also oxidative stress in infants with a univentricular heart defect 
undergoing bidirectional Glenn procedure.  
Design: A double-blind, placebo-controlled, randomized clinical trial.  
Setting: Operation theatre and pediatric intensive care unit of a university hospital.  
Participants: Twenty-nine infants undergoing bidirectional Glenn procedure with or without aortic 
arch or pulmonary arterial repair.  
Interventions: After anesthesia induction, the patients received intravenously either 30 mg/kg of 
methylprednisolone (n=15) or the same volume of saline as placebo (n=14).  
Measurements and Main Results: Plasma interleukin-6, interleukin-8 and interleukin-10 
(biomarkers of inflammation) as well as 8-hydroxydeoxyguanosine concentrations (a biomarker of 
oxidative stress) were measured at four different time points: preoperatively, during CPB, after 
protamine administration, and six hours postoperatively. The study parameters did not differ 
between the study groups preoperatively. Methylprednisolone reduced the pro-inflammatory 
cytokines interleukin-6 and interleukin-8 and increased the anti-inflammatory cytokine interleukin-
10 postoperatively. Despite reduced inflammation, there were no differences in 8-
hydroxydeoxyguanosine between the methylprednisolone and placebo groups.  
Conclusions: Pro-inflammatory reaction and increase in free radical stress were not interrelated 
during congenital heart surgery in cyanotic infants with a univentricular heart defect undergoing 
bidirectional Glenn procedure. High-dose methylprednisolone was ineffective in attenuating free 
radical stress. 
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Introduction   
 
Corticosteroids are used in pediatric cardiac surgery to attenuate the systemic inflammatory 
reaction caused by cardiopulmonary bypass (CPB) and surgery.1 In randomized studies, 
corticosteroids have also been reported to have cardioprotective effects.2-4 On the other hand, 
steroids have many side effects and may even be associated with increased morbidity, particularly 
in lower-risk patients.5 The overall benefit of perioperative steroids remains controversial. 
Biochemical evaluation of corticosteroid effects in pediatric heart surgery is mainly based on 
measurement of pro- and anti-inflammatory cytokines. Cytokines, however, are merely 
mediators/regulators but not effectors of pathophysiological processes. Biochemical mechanisms 
relevant to tissue destruction and organ dysfunction should be studied for better understanding of 
corticosteroid effects in pediatric heart surgery. We have previously shown that high-dose 
methylprednisolone (MP) reduces activation of neutrophils, which are important first line actors in 
ischemia/reperfusion injury.6 Furthermore, we have observed that MP conserves endothelial 
glycocalyx, a major determinant of capillary permeability and tissue edema.7  
 
The overall prognosis for congenital heart diseases has improved. Children with the single ventricle 
circulation treated with palliative surgery are still those associated with significant morbidity and 
considerably higher risk of mortality than children who undergo other types of cardiac surgery.8 As 
one pathophysiological mechanism of morbidity, CPB is associated with production of free oxygen 
radicals that cause degradation of macromolecules and tissue destruction.9 The radical stress 
during cardiac surgery is stronger in children with cyanotic than non-cyanotic cardiac defects.10,11 
In children with a univentricular heart defect, the extent of lipid peroxidation correlates inversely 
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with postoperative lung function.12 In cyanotic patients, compared to hyperoxia, normoxia during 
CPB reduces not only lipid peroxidation but also biomarkers of heart, brain and liver damage.10,11,13 
 
Free oxygen radicals are derived from molecular oxygen with one unpaired electron, and can 
oxidize mitochondrial and nuclear DNA during ischemic conditions.14 When guanine is oxidized to 
7,8-dihydro-8-oxoguanine it can cause carcinogenic transversion mutations, as it can pair up with 
both adenine and cytosine.15 Utilizing rapid repair mechanisms to maintain their genomic integrity, 
cells recognize and excise 7,8-dihydro-8-oxoguanine by OGG1 gene-encoded 8-oxoguanine DNA 
glycosylase. As a result, DNA is repaired. The stable end-product, 8-hydroxydeoxyguanosine (8-
OHdG), can be reliably measured as it is transferred out of the cell and ultimately to the urine.16  
 
Inflammation is also associated with increased oxidative stress. Unlike mitochondrial free radicals 
produced in electron transport chain during ischemia/reperfusion injury, immune activated cells 
actively generate reactive oxygen species via the nicotinamide adenine dinucleotide phosphate 
oxidase system.17 Surgical repair for congenital cardiac malformations results in vascular 
inflammation, endothelial dysfunction, and subsequent imbalance in cellular redox regulating 
enzymes leading to increased oxidative stress.18,19 MP reduces the pro-inflammatory reaction in 
pediatric heart surgery.4,20 In experimental conditions, MP increases cardiac anti-oxidative 
capacity.21 We hypothesized that high-dose MP reduces inflammatory reaction and thereby also 
oxidative stress in children with a univentricular heart defect undergoing bidirectional Glenn 
procedure. 
  





Ethics and Informed Consent 
The study protocol was approved by the Ethics Committee of Helsinki University Hospital and by 
the Finnish Medicines Agency. It was registered in the European Union Drug Regulating 
Authorities Clinical Trials (Eudra-CT 2008-007413-76).  The study was conducted according to the 
declaration of Helsinki. Written informed consent was obtained from the parents of each 
participating patient before the study commenced. 
 
Study Design 
In this randomized (sealed envelope) double-blind study, thirty infants of 2-12 months of age 
undergoing bidirectional Glenn procedure for palliation of a univentricular heart defect were 
administered with either 30 mg/kg of intravenous MP or an equal volume of saline as placebo at 
anesthesia induction. There was one dropout because of cancellation of surgery after 
randomization. Exclusion criteria were preoperative steroid treatment and prematurity under 
gestational age of 36 weeks. The study drug was administered after anesthesia induction and 
collection of the first study plasma sample. A pharmacist, not otherwise involved in the patient 
care, prepared the study drug solutions. All personnel at the operation theatre, intensive care unit 
(ICU) and ward were blinded against the allocation of the patients to the study groups. The 
syringes of the study drug were covered with non-transparent paper foil. No additional 








Balanced general anesthesia was attained with sufentanil, pancuronium, propofol or s-ketamine 
and sevoflurane. All operations were undertaken using CPB. Myocardial protection and CBP were 
accomplished by using the methods described previously.22 During CPB, partial oxygen tension 
(pO2) in the arterial line was maintained above 12 kPa. In the pediatric intensive care unit (PICU), 
arterial oxygen saturation (spO2) was either above 80% or achieved the presumed optimal target 
of the corrected cardiac defect. However, both during CPB and in the PICU, hyperoxia above the 
target value was avoided. Eight patients (four in both study groups) received cardioplegia following 
aortic cross clamp. In these patient, 1 ml/kg of mannitol was administered at the time of aortic 
declamping. Antegrade cerebral perfusion was used for two patients (one in each study groups) 
during aortic arch correction. Aortic cross clamp was not used for 21 patients. Four mg/kg of 
sodium heparin was used for anticoagulation before CPB and the Hepcon HMS Plus (Medtronic, 
Minneapolis, MN) was used to obtain the target heparin concentration of 6 IU/ml during CPB. 
Protamine sulphate was used to reverse the anticoagulant effect of heparin after weaning from 
CPB. All study patients received a bolus of 30000 IU/kg of aprotinin before CPB and a continuous 
infusion of 30000 IU/kg/hour during CPB.  
 
Milrinone was used as the first line inotropic drug. Epinephrine and norepinephrine were added to 
milrinone for hemodynamic support if needed. Levosimendan was used in two patients in the MP 
group and in one patient in the placebo group. One patient in both groups received phenylephrine 
and one patient in the MP group received vasopressin for unstable hemodynamics. The inotropic 
score was calculated as previously described.22 Inhaled nitric oxide was administered to five 
patients in the MP and to seven patients in the placebo group. Insulin was administered at ICU 
according to the decision of the clinician on duty. In general, insulin infusion was started when 
blood glucose was more than 12 mmol/l in two consecutive measurements.  
 





Five ml of arterial blood were collected into tubes containing sodium citrate at four different time 
points: T1) after anesthesia induction before administration of study drug (“preop”), T2) 30 minutes 
after initiation of CPB (“on CPB”), T3) five minutes after administration of protamine (“after CPB”) 
and T4) six hours after cessation of CPB (“6 h”). Plasma was separated immediately by 
centrifugation and stored at –70 ºC until analysis. At time points T1 to T4, Interleukin-6 (IL-6), IL-8 
and IL-10 (Quantikine, R&D Systems, Abington, UK) and 8-hydroxydeoxyguanosine (Highly 
Sensitive 8-OHdG Check ELISA kit, The Japan Institute for the Control of Aging, Fukuroi, Japan) 
were determined using commercial ELISA kits following manufacturer’s instructions. Blood glucose 




At the time of the study design, previous data were available on corticosteroid treatment in 
pediatric congenital heart surgery using IL-6 as an index of the inflammatory reaction.23 In that 
study, IL-6 was measured using a commercial ELISA kit of the same manufacturer as in the 
present study. As in two previous MP trials of our research group,4,24 power analysis indicated that 
12 patients would be required to demonstrate a 20% difference in IL-6 values in either direction 
between the two study groups (α=0.05, 1-β=0.80). The applied power analysis is for t-test and 
assumes normal distribution. For the Mann-Whitney test 10% increase in the patient number is 
needed.25 We used non-parametric tests because of the small sample size. Changes as a function 
of time within a group were tested with Friedman’s test. Differences between the groups were 
tested with Mann-Whitney U test. The 2 test was used for comparison of frequencies between the 
groups. In comparison of cytokine and 8-hydroxydeoxyguanosine concentrations between the 
study groups, Bonferroni-Holm correction was used due to the three (interleukins and 8-
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hydroxydeoxyguanosine) or four (blood glucose) postoperative sampling time points. Otherwise, p-
values less than 0.05 were considered as statistically significant. Data are expressed as medians 
and interquartile ranges (IQR) or patient numbers or depicted as box plots. SPSS 25 for Windows 
(SPSS Inc., Chicago, IL, USA) was used for data analyses. 





There were no significant differences in the demographic and operative data between the MP and 
placebo groups (Table 1). Insulin infusion was started in 3 patients in the MP group and no patients 
in the control group (p=0.08). Blood glucose levels were significantly higher in the MP than the 
placebo group at time points T2 [10.0 (8.4-11.7) mmol/L vs. 7.2 (6.2-8.5) mmol/L, p=0.001], T3 
[11.7 (8.3-12.9) mmol/L vs. 6.6 (5.5-8.8) mmol/L, p=0.001], T4 [7.8 (6.1-10.8 mmol/L vs.5.6 (5.0-
6.3) mmol/L, p=0.006] and the first postoperative morning [12.8 (10.8-15.5) mmol/L vs. 10.1 (8.9-
11.9) mmol/L, p=0.006] but not preoperatively [4.7 (4.6-5.3) mmol/L vs. 4.7 (4.5-4.9) mmol/L, 
p=0.40]. Also, leukocyte levels were higher in the MP group at PICU arrival and the first 
postoperative morning (Table 2). There were no differences in other clinical and physiological 
parameters between the study groups (Table 2). 
 
There were no statistically significant differences in plasma cytokine concentrations preoperatively 
(Table 3). Plasma concentrations of all cytokines increased significantly in both study groups (all 
p<0.001 in Friedman’s test, Table 3). Plasma concentrations of the pro-inflammatory cytokines IL-6 
and IL-8 were higher and those of the anti-inflammatory cytokine IL-10 were lower in the placebo 
than the MP group (Table 3). 
 
There were no statistically significant differences in plasma 8-hydroxydeoxyguanosine 
concentrations preoperatively (Fig. 2). 8-hydroxydeoxyguanosine concentrations increased 
significantly as a function of time in both study groups (p<0.001 for MP and p=0.002 for placebo in 
Friedman’s test, Fig. 1). At six hours postoperatively, 8-hydroxydeoxyguanosine concentrations 
tended to be higher in the MP than the placebo group (p=0.027) but the difference did not reach 
statistical significance level of p<0.017 after Bonferroni-Holm correction that was conducted due to 
three repeated postoperative measurements.  
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Additionally, we conducted statistical analyses among patients with isolated BDG (13 patients in 
MP group and 8 patients in placebo group, Table 3). The results of cytokine concentrations as well 
as blood glucose and leukocyte levels in the isolated BDG patients were comparable with the 
results of all the patients. Likewise, there were no statistically significant differences in plasma 8-
hydroxydeoxyguanosine concentrations between the study groups although the concentrations 
were slightly higher in the MP groups (data not shown).  





In terms of pro- and anti-inflammatory cytokines, high dose MP resulted in a substantially reduced 
inflammatory reaction in our patients undergoing BDG procedure. Reduced inflammation, however, 
did not lead to decreased radical stress. The observation is contradictory to our original hypothesis 
but eventually not surprising in the light of existing literature. Dissociation of radical stress from 
inflammation has previously been reported in pediatric cardiac surgical patients. In cyanotic 
children, hyperoxia, compared with normoxia, increased radical stress measured as 8-isoprostane 
while cytokines IL-6, IL-8 and IL-10 as well as the complement degradation product C3a remained 
unchanged.13 In oxidative stress, ascorbate/dehydroascorbate redox state is shifted towards 
oxidized dehydroascorbate,26 and malondialdehyde as a toxic, reactive compound is  produced 
from polyunsaturated fatty acids.27 In children with various cyanotic and non-cyanotic cardiac 
defects, decreased ascorbate, increased dehydroascorbate and increased malondialdehyde 
plasma concentrations occurred at the time of aortic cross-clamp removal several hours before the 
peak of the pro-inflammatory cytokines IL-6 and IL-8.28 Taken together, the association of radical 
stress with inflammation is not straightforward.  
 
There are only few studies on the effects of corticosteroids on radical stress in cardiac 
ischemia/reperfusion injury. Administration of MP before cardiac ischemia improved tissue 
antioxidative capacity during reperfusion in the ex vivo model of Langendorff perfused heart.21 The 
results in a clinical scenario have been more modest. In adult patients undergoing coronary artery 
bypass grafting, MP reduced only cardiac lipid peroxidation measured as the trans-coronary 
difference in concentrations of plasma malondialdehyde but did not have any effect on oxidative 
state of glutathione, oxidative modification of proteins or postoperative occurrence of arrhythmias.29 
In our patients, MP did not reduce radical stress measured by plasma concentrations of 8-
hydroxydeoxyguanosine, a specific and stable marker of hydroxyl radical mediated DNA damage.30 
Conspicuously at six hours postoperatively there was a non-significant tendency of radical stress to 
be higher in the MP group than the placebo group. In accordance, an extensive meta-analysis 
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showed increased oxidative stress in vertebrates after glucocorticoid treatment.31  
As the weaknesses of the present study, the power analysis was based on plasma IL-6 
concentrations. There are not applicable published data on 8-hydroxydeoxyguanosine 
concentrations in the present clinical context. Thus, the obtained results of 8-
hydroxydeoxyguanosine may be hampered by insufficient statistical power. Still, because 8-
hydroxydeoxyguanosine tended to be higher in the MP than the control group, it can fairly safely be 
concluded that with the used biomarker, MP was at least ineffective in reducing radical stress in 
our patients. Due to small patient number, we could not evaluate the effect of MP on meaningful 
clinical outcomes. Furthermore, aprotinin was administered in every patient. Because aprotinin 
possesses anti-inflammatory properties besides the anti-fibrinolytic effect, it may have influenced 
on the results. Relatively homogenous patient selection is a strength of this double-blinded, 
placebo-controlled, randomized clinical study. Most clinical trials on corticosteroids in pediatric 
heart surgery are hampered with vast age range and combination of various congenital heart 
defects of the patients. The age range (2-12 months) of our patients was fairly narrow. There was, 
however, heterogeneity also in the present study, because half of the patients underwent either 
aortic arch or pulmonary arterial correction beyond isolated bidirectional Glenn procedure Still, the 
intervention arms were well in balance with major surgical and therapeutic procedures, such as the 
use of aortic cross clamp, antegrade cerebral perfusion and vasoactive drugs. Finally, children with 
a cyanotic heart defect are especially susceptible to radical stress in heart surgery.10,11 Thus, the 
chosen patient cohort is relevant for the present study. 
As a conclusion, despite substantial reduction of the pro-inflammatory reaction, high-dose MP was 
ineffective in attenuating free radical stress in a patient group prone to oxidative stress, i.e. 
cyanotic infants undergoing bidirectional Glenn procedure. According to the present results, 
reduced free radical stress probably is not a potential therapeutic biochemical mechanism of 
corticosteroid treatment. The overall benefit of corticosteroids in pediatric heart surgery is 
controversial. Two ongoing large-scale trials (Clinicaltrials.gov: NCT01579513 and NCT03229538) 
will provide us more information to this intriguing question.  
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Figure 1. Plasma concentrations of 8-hydroxydeoxyguanosine in the control (white bars) and the 
MP (grey bars) groups preoperatively (preop), at 30 min after start of CPB (on CPB), 5 minutes 
after protamine (after CPB) and 6 hours postoperative (6 h). No statistically significant differences 
were observed between the study groups after Bonferroni-Holm correction of repeated 
postoperative measurements (see the Results). Data are expressed as box plots (median and 
interquartile range) with whiskers (minimum and maximum). 
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Table 1. Patient demographic and operative data. 





Age (months) 6.0 (4.8-8.3) 6.7 (5.6-8.1) 0.74 
Weight (kg) 6.8 (6.1-7.8) 7.2 (5.8-8.4) 0.41 
Male/female (n) 10/5 7/7 0.36 
CPB support time (min) 55 (46-103) 66 (59-81) 0.20 
Aortic cross clamp (n) 4 4 1.0 
Aortic cross clamp time (min) 20 (7-64) 49 (22-89) 0.31 
ACP (n) 1 1 1.0 
ACP time (min) 19 57  
 Lowest temperature (°C) 34.0 (32.0-34.0) 34.0 (31.5-35.0) 0.79 
Cardiac defects    
    HLHS 8 8  
    TA 1 1  
    Other UVH 6 5  
Surgical correction   0.07 
    BDG (n) 13 8  
    BDG and aortic arch reconstruction (n) 2 1  
    BDG and LPA / RPA reconstruction (n) 0 4  
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    BDG and CoA angioplasty (n) 0 1  
Primary sternal closure (n) 14 13 0.85 
Late re-sternotomy (n) 1 0 0.33 
Values are medians and interquartile ranges. Abbreviations: ACP, antegrade cerebral perfusion; 
BDG, bidirectional Glenn procedure; CoA, coarctation of the aorta; CPB, cardiopulmonary bypass; 
HLHS, hypoplastic left heart syndrome; MP, methylprednisolone; LPA, left pulmonary artery; RPA, 
right pulmonary artery; TA, tricuspid valve atresia; UVH, univentricular heart. 
 
Table 2. Clinical data. 





Arrival to PICU    
   Lactate (mmol/L) 1.3 (0.9-1.8) 1.1 (0.9-1.5) 0.25 
   White blood cell count (E9/L) 9.6 (7.8-12.3) 7.65 (6.0-9.5) 0.05 
   Rectal temperature (oC) 36.3 (35.6-36.5) 36.0 (35.5-36.5) 0.26 
   Inotropic score 15.0 (13.0-25.0) 17.0 (11.8-22.5) 0.79 
   Central venous saturation (%) 55.9 (45.3-57.7) 46.4 (37.5-59.3) 0.62 
The first postoperative day #    
   Lactate (mmol/L) 1.0 (0.7-1.4) 1.1 (0.7-1.5) 0.60 
   White blood cell count (x109/L) 12.8 (10.8-15.5) 10.1 (8.9-11.9) 0.01 
   Rectal temperature (oC) 37.6 (37.3-38.2) 38.1 (37.5-38.5) 0.17 
   Inotropic score 5.0 (5.0-7.0) 5.0 (5.0-6.8) 0.91 
   Central venous saturation (%) 55.8 (46.0-59.9) 59.7 (45.9-63.2) 0.37 
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   NT-proBNP (ng/L) 4332 (1952-11172) 2362 (1518-9735) 0.33 
Ventilatory treatment (days)    
PICU stay (days) 2 (2-4) 2 (2-5) 0.96 
PICU mortality 1 0 0.33 
#Measured on the first POD at 6:00 a.m., except inotropic score was calculated at 12:00 a.m. 
Values are medians and interquartile ranges. Abbreviations: NT-proBNP, N-terminal pro-B-type 
natriuretic peptide; PICU, Pediatric Intensive Care Unit. 
Table 3. Plasma cytokine concentrations. 





IL-6 (pg/mL)    
T1 (preop) 2.6 (1.8-3.0) 2.8 (2.2-6.7) 0.35 
T2 (on CPB) 2.3 (1.8-4.8) 5.5 (2.7-8.3) 0.03* 
T3 (after CPB) 2.6 (0.7-5.6) 5.4 (3.3-19.4) 0.02* 
T4 (6 h) 38.9 (31.2-53.8) 448.1 (140.4-627.2) <0.001* 
IL-8 (pg/mL)    
T1 (preop) 14.0 (11.7-17.2) 14.1 (10.7-18.5) 0.91 
T2 (on CPB) 18.3 (13.7-21.0) 19.9 (17.2-23.7) 0.11 
T3 (after CPB) 34.4 (25.0-45.3) 62.7 (41.8-119.5) 0.02* 
T4 (6 h) 24.5 (22.5-46.5) 59.6 (50.1-113.9) <0.001* 
IL-10 (pg/mL)    
T1 (preop) 0.5 (0.0-1.7) 0.5 (0.0-1.7) 0.85 
T2 (on CPB) 16.2 (7.6-45.1) 1.7 (0.9-5.6) <0.001* 
T3 (after CPB) 342.0 (183.6-990.4) 25.7 (9.4-57.4) <0.001* 
T4 (6 h) 82.2 (27.4-97.0) 20.6 (7.6-35.6) 0.001* 
*, statistically significant after Bonferroni-Holm correction of repeated measure at the three 
postoperative time points. 
         
